Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq Copenhagen: GEN) announced today that …
Potentially first new class of antibiotics in Phase III development against Gramnegative pathogens in 50 years Polyphor today announced the enrollment of the first patient …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
